StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Sign in to jot down a private note about GLUE. Only you ever see it.
External sites have their own terms, paywalls, and accuracy standards. Stonvex doesn't endorse the content there.
Three bull points, three bear points, and one “what would change my mind” line — both sides forced onto one screen as a research note rather than a tip sheet.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $4.21M | $123.67M | $120.89M | $108.12M |
Operating Income | $-50.03M | $-54.21M | $-4.49M | $28.48M |
Net Income | $-44.50M | $-38.60M | $7.51M | $-12.29M |
EPS (Diluted) | $-0.45 | $-0.46 | $0.09 | $0.42 |
Total Assets | $736.43M | $448.66M | $459.84M | $359.59M |
Total Liabilities | $214.51M | $215.60M | $214.00M | $91.51M |
Cash & Equivalents | $159.86M | $129.88M | $208.34M | $69.43M |
Free Cash Flow OCF − CapEx | $-39.24M | $-27.50M | $16.28M | $-83.49M |
Shares Outstanding | 84.32M | 65.54M | 61.79M | 61.72M |
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.